9amHealth has raised $26 million in Series B financing to expand its AI-driven virtual specialty care platform for chronic conditions. The funding round was led by Define Ventures, with participation from SemperVirens, Catalio Capital Management, and NewHealth Ventures. As part of the investment, Lynne O’Keefe, Founder and Managing Partner at Define Ventures, will join the company’s Board of Directors.
The company, which initially focused on obesity, diabetes, and hypertension management, plans to broaden its services to address a wider range of chronic conditions that account for a significant share of employer healthcare and pharmacy costs. According to 9amHealth, these high-cost conditions can represent up to 70% of employer pharmacy spending.
Managing chronic disease and specialty medication utilization has become an increasing challenge for enterprise employers, health plans, and pharmacy benefit managers. 9amHealth positions its platform as a way to streamline care delivery through a combination of specialized clinical protocols, at-home diagnostics, medication management, and AI-enabled operational workflows.
Frank Westermann, CEO and Co-Founder of 9amHealth, said the company’s infrastructure enables the organization to scale complex care management programs more efficiently by integrating clinical expertise with automation technologies.
The company stated that it has already demonstrated more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers. Its care model includes 24/7 access to endocrinologists, obesity medicine specialists, and clinical pharmacists, alongside lifestyle support and home-based lab testing intended to support long-term disease management.
The expansion strategy builds on increasing employer demand for support managing cardiometabolic conditions, particularly amid rising utilization of GLP-1 therapies. 9amHealth said the new funding will support development of a technology platform designed to coordinate repeat interventions and ongoing specialty care at scale.
The company also aims to address what it describes as “Information Asymmetry” in healthcare spending by creating a unified layer of clinical intelligence for employers, insurers, and PBMs. Through standardized care pathways and integrated data insights, the platform seeks to improve management of high-cost patient populations while reducing fragmentation across specialty care services.
With the new financing, 9amHealth plans to continue expanding its enterprise reach and clinical capabilities as employers increasingly prioritize cost control strategies tied to chronic disease management.
Click here for the original news story.
